Welcome to our dedicated page for Cue Biopharma news (Ticker: CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma stock.
Cue Biopharma Inc (NASDAQ: CUE) is a clinical-stage biopharmaceutical company pioneering targeted immunotherapies through its innovative Immuno-STAT platform. This page serves as the definitive source for official company announcements, research developments, and strategic updates.
Investors and industry observers will find curated press releases covering clinical trial progress, regulatory milestones, and partnership announcements. Our collection includes updates on CUE-100 series candidates for oncology applications and autoimmune disease programs, along with financial reporting and executive commentary.
All content is sourced directly from company filings and authorized communications, ensuring reliability for those monitoring advancements in T cell-modulating therapies. Key focus areas include phase 1/2 trial results, platform technology enhancements, and collaboration updates with leading research institutions.
Bookmark this page for streamlined access to Cue Biopharma's latest scientific achievements and corporate developments in the competitive immunotherapy landscape. Check regularly for real-time updates on this innovative biologics developer.
On April 25, 2023, Cue Biopharma (Nasdaq: CUE) announced the appointment of Dr. Pamela D. Garzone to its board of directors. Dr. Garzone brings over 25 years of experience in the healthcare and pharmaceutical sectors, particularly in drug development and regulatory leadership. Her expertise spans various therapeutic areas, including immuno-oncology, which aligns with Cue Biopharma’s focus on developing innovative biologics aimed at engaging disease-specific T cells within patients. Cue Biopharma aims to enhance treatment options for cancer and autoimmune diseases using its proprietary Immuno-STAT™ platform. The CEO, Daniel Passeri, expressed confidence that Dr. Garzone’s experience will provide strategic insights as the company advances its clinical and preclinical pipeline.
Cue Biopharma (CUE) has announced the appointment of Patrick Verheyen to its Board of Directors, bringing over 35 years of experience from Janssen Pharmaceutical. Verheyen's expertise in business development and M&A is expected to enhance Cue's corporate growth and current drug candidates, CUE-101 and CUE-102. Daniel Passeri, CEO of Cue Biopharma, expressed enthusiasm for Verheyen's insights, aiming to broaden the company’s strategic initiatives in immunotherapy for autoimmune diseases and cancer. Verheyen's past achievements include leading significant acquisitions at Janssen, which expanded its pipeline and established a global innovation presence.
On March 21, 2023, Cue Biopharma reported significant advancements in its clinical initiatives and financial results for 2022. The FDA accepted its IND application for CUE-102 targeting WT1-expressing cancers and started a Phase 1 trial. CUE-101 received Fast Track Designation for HPV+ head and neck cancers. The 2022 collaboration revenue dipped to $1.2 million from $14.9 million in 2021, while net losses increased to $53 million, affected by reduced research funding and expenses. However, cash reserves rose to $76.3 million, expected to support operations until late 2024. The company aims to present updated data on its oncology programs in upcoming conferences.
FAQ
What is the current stock price of Cue Biopharma (CUE)?
What is the market cap of Cue Biopharma (CUE)?
